Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. The company demonstrates solid financial health with a current ratio of 1.85 and a debt-to-equity ratio of 0.76.
Cyborg Score Rationale
Adjusted earnings per share increased by 11.5% to $4.47, with projected 2026 organic net sales growth of 8% to 9.5% and adjusted EPS expected to range from $14.90 to $15.10. Operating margin stands at 19.63% and net margin at 12.07%, reflecting efficient cost management and strong profitability.
Top Insights
Stryker achieved 11% organic sales growth in Q4 2025, surpassing $25 billion in annual sales.
Adjusted earnings per share increased by 11.5% to $4.47, driven by sales growth and improved margins.
Analyst sentiment remains positive, with a target price of $426.89 and a recommendation score of 1.9, indicating a 'Buy' consensus.
Adjusted operating margin widened approximately 100 basis points to 30.2% in Q4, with management emphasizing margin expansion and new product launches as 2026 drivers.
Named Competitors
Zimmer Biomet — Orthopedic implants and surgical equipment
Smith & Nephew — Orthopedic and surgical products
Medtronic — Medical devices and patient monitoring
Johnson & Johnson — Diversified healthcare including orthopedic devices
Recent Developments
(January 2026) Achieved 11% organic sales growth in Q4 2025, surpassing $25 billion in annual sales
(January 2026) Projected 2026 organic net sales growth of 8% to 9.5%, with adjusted EPS expected to range from $14.90 to $15.10
(February 2026) Director Ronda E. Stryker sold 250,000 shares on February 4th at an average price of $362.92
Open the full interactive Stryker Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.